Libella Gene Therapeutics

Quick facts

Phase 1 pipeline

• AAV-hTERT · Rare Disease
  AAV-mediated delivery of the hTERT gene

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Libella Gene Therapeutics portfolio CI brief
• Libella Gene Therapeutics pipeline updates RSS